Novartis AG

NOVN

CH0012005267

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2024-09-17 - Bank of America Global Healthcare Conference

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

NOVARTIS : Onboarding healthy earnings momentum

August 01, 2024 at 10:24 am

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

116.45USD

Average target price

116.54USD

Spread / Average Target

+0.08%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Swiss Exchange Other stock markets 11:31:25 2024-09-17 EDT			5-day change	1st Jan Change
98.03 ^CHF	-0.39%		-0.79%	+15.51%

09-16	Liquidia Says United Therapeutics' Interference Found by US Court to Have Caused Losses of Over $137 Million	MT
09-16	Kyverna Therapeutics, Inc. Announces CEO Changes	CI

Liquidia Says United Therapeutics' Interference Found by US Court to Have Caused Losses of Over $137 Million	09-16	MT
Kyverna Therapeutics, Inc. Announces CEO Changes	09-16	CI
Novartis' Breast Cancer Combo Drug Lowers Recurrence Risk in Late-stage Trial	09-16	MT
Novartis: results of breast cancer analysis	09-16	CF
Novartis' Kisqali Reduces Breast Cancer Recurrence by Nearly One-Third, Trials Show	09-16	DJ
Novartis Kisqali(R) shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer	09-16	DJ
NOVARTIS AG : Gets a Buy rating from UBS	09-11	ZD
EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies	09-06	AN
Veeva Systems: leader in cloud solutions for the life sciences industry	09-06
NOVARTIS : Goldman Sachs no longer Buy	09-05	CF
Such a long wait	09-05
Goldman Sachs Downgrades Novartis to Neutral From Buy, Adjusts Price Target to $121 From $119	09-05	MT
Novartis shares fall back as Morgan Stanley takes a break	09-05	CF
Voyager Therapeutics Gets Capsid License for Gene Therapy Program From Novartis	09-05	MT
Goldman Sachs Downgrades Novartis to Neutral, Trims PT	09-05	MT
EDX Medical Group Names New Chief Commercial Officer	09-05	MT
NOVARTIS AG : Goldman Sachs is Neutral	09-05	ZD
Novartis Starts Construction of New Radioligand Therapy Sites in US	09-04	MT
Novartis: two new radioligand units in the USA	09-04	CF
NOVARTIS : Jefferies upgrades to 'hold', share price consolidates	09-03	CF
Jefferies Downgrades Novartis to Hold, Lowers PT	09-03	MT
Jefferies Downgrades Novartis to Hold From Buy	09-03	MT
US will still pay at least twice as much after negotiating drug prices	09-03	RE
NOVARTIS AG : From a Buy to Neutral rating by Jefferies	09-03	ZD
Siemens Healthineers wants to expand nuclear diagnostics with acquisition	08-30	RE

Novartis AG

Equities